Cancer Biomarkers Market

Global Cancer Biomarkers Market Size By Cancer Type (Breast, Lung, Leukemia, Colorectal, Melanoma, and others), By Technology (Cytogenetics Based Tests, Imaging Technologies, Omic Technologies, and Immunoassays), By Application (Drug Discovery and Development, Diagnostics, Risk Assessment, Prognostics, and Others), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2022 to 2030

Base Year: 2021 Historical Data: 2019-20
  • Report ID: TBI-12718
  • Published Date: Apr, 2022
  • Pages: 236
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global cancer biomarkers market is expected to reach USD 48.2 Billion by 2030, at a CAGR of 13.2% during the forecast period 2022 to 2030. The rising incidences of various kinds of cancers such as prostate, breast, and lung cancer are expected to drive the market for cancer biomarkers over the forecast period.

Market Overview:

Cancer markers are molecules secreted by the tumor or due to a specific response to the body, which indicates the presence of cancer. Biomarkers help detect cancer in the initial stage and make cancer treatment easier with non-invasive high-speed diagnosis using tools such as genomics and proteomics. The diagnosis and analysis of various cancer markers for prevention and treatment using different diagnostic techniques is the best way to get rapid treatment results. Multiple biomarkers include proteins, antibodies, peptides, and nucleic acids. The presence of these biomarkers in blood, urine, tissues, serum, and other fluids indicates the presence of disease. Biomarkers are used in various applications such as drug discovery and development, diagnosis, prognostics, risk assessment, and others. The increasing need for personalized medicine to treat cancer and other diseases increases the demand for biomarkers in drug discovery and development. Moreover, an increase in investment from the public & private sectors and governments towards research & development for finding proper and quick diagnostics of cancer has a positive impact on the market. In addition, the rise in technological advancements, the importance of biological & targeted drug therapies, reliability, and accuracy of cancer biomarkers also propel the market's growth.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:

  • Increasing incidences of cancer

The increasing incidences of various types of cancers such as breast, lung, leukemia, colorectal, melanoma, and others drive the market's growth. The research and development taking place for finding the proper treatment for the cure of the disease at an affordable price contribute to the market's growth. When the disease diagnosis is made early, it helps treat the condition accurately.

Restraints:
  • Technical issues in sample collection

The technical issues in sample collection are a significant restraint for the market's growth as sample collection is the initial stage in the cancer diagnosis. The sample collection requires stringent quality control, and the samples collected need to be stored under the right conditions to avoid the loss of samples. Moreover, different samples are needed for diagnosis at various stages, such as screening, risk detection, and monitoring processes, which restrain the market growth during the forecast period.

Opportunities:
  • Rising demand for personalized medicines

The rising demand for personalized medicines is an opportunity for the market's growth during the forecast period as it is the most beneficial path for the treatment of cancer in individual patients. Cancer biomarkers play an essential role in the production of personalized medicines which provides potential growth opportunities for the players operating in the market.

Challenges:
  • Lack of reimbursement policies

Even though the incidents of cancer are increasing rapidly, which requires diagnosis in massive numbers with accurate results, but due to lack of reimbursement policies in emerging and developing economies is one of the factors challenging the growth of the cancer biomarkers market during the forecast period.

Segmentation Analysis:

The global cancer biomarkers market has been segmented based on cancer type, technology, application, and regions.

  • The cancer type segment is divided into breast, lung, leukemia, colorectal, melanoma, and others. The breast cancer segment dominated the market, with a market share of around 22% in 2021. The increasing breast cancer cases and awareness regarding breast cancer diagnosis are factors driving the segmental growth. The rising research activities for the rapid and accurate diagnosis of breast cancer is the primary factor driving the market.
  • The technology segment is divided into cytogenetics-based tests, imaging technologies, omic technologies, and immunoassays. Over the forecast period, the omic technologies segment is expected to grow at the fastest CAGR of 15.3%. The rising research development on cancer biomarkers due to the rising incidences of cancer is driving the segment's growth. The segment is also growing owing to its efficiency in diagnosing cancer at an early stage.
  • The application segment is divided into drug discovery and development, diagnostics, risk assessment, prognostics, and others applications. In 2021, the diagnostics segment dominated the market, accounting for around 33% of global revenue. The rising cases of different types of cancer which require diagnosis at the early stage are driving the market's growth. Moreover, the awareness regarding cancer and people becoming more cautious about their health is also driving the segment growth.
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America emerged as the largest market for the global Cancer Biomarkers market, with a 42.2% share of the market revenue in 2021.

  • North America currently dominates the cancer biomarkers market with a 42.2% share of the market revenue in 2021. The increasing incidences of cancer and its type in the regions and the need for diagnosis is propelling the market's growth. The growing research and development on cancer biomarkers and advancements in technology for the development and improvement of cancer biomarkers are anticipated to boost the market growth. The improved expenditure on healthcare facilities by the government and private and public companies is also likely to promote the development of the market in North America during the forecast period.
  • The Asia Pacific is projected to be the fastest-growing during the forecast period. Countries like Japan and China face a large pool of cancer patients, driving the market growth. Moreover, the rise in affordability and awareness of advanced cancer treatments further propels the market growth in the Asia-Pacific region.

North America region Cancer Biomarkers Market Share in 2021 - 42.2%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances, and partnerships to improve their market position in the global cancer biomarkers market industry.

  • In April 2021, Elecsys Anti-p53 immunoassay was launched by F. Hoffmann-La Roche Ltd. to help diagnose various types of cancer.
  • April 2020, the therascreen BRAF test was launched by Qiagen N.V. as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen for the diagnosis of metastatic colorectal cancer.

List of Key Market Players:

  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Bio-Rad Laboratories
  • PerkinElmer
  • F.Hoffmann-La Roche Ltd.
  • Qiagen N.V.
  • Exact Sciences Corporation
  • Thermo Fisher Scientific
  • Siemens AG

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities
  • Consulting And Research Firm
  • Venture capitalists
  • Third-party knowledge providers
  • Value-Added Resellers (VARs)

Report Description:

  • Global Cancer Biomarkers market, Industry Analysis, Trends, Analysis and Forecast, 2022 to 2030 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2021 is considered the base year of the report. 2019 and 2020 are considered as the historic years and 2022 to 2030 are the forecast years. The global cancer biomarkers market is based on revenue (USD Billion). The report incorporates the market study based on revenue. The study covers the market share revenue/market share/volume for each of the segments, regions, and countries catering to the global cancer biomarkers market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses the relative data & information, which have been validated by the leading industry professionals and experts across the globe. The research report also delivers an outline of the attractiveness of cancer biomarkers based on cancer type, technology, application, and regions which are deduced and formulated based on their growth rate (CAGR), market size, and attractiveness by analyzing the present and prospects to fathom market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to the global cancer biomarkers market. This offers vital and in-depth insights to depict the overall market scenario.
  • The report offers a detailed study for the company profiles of key organizations operating in the global cancer biomarkers market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario.
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis to provide business-related data and information. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company's growth and development to sustain and survive in the long run.
  • Along with that, the report also focuses on the market-related driving factors, growth limitations (restraints), potential industry opportunities, significant trends, and development which act as a key potential for the investors.
  • Potential growth prospects along with the penetration rate analysis of the product (market-related i.e., global cancer biomarkers market) are covered to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the cancer biomarker market was valued at USD 15.8 billion in 2021 to USD 48.2 billion by 2030.

The global cancer biomarker market is growing at a CAGR of 13.2% during the forecast period 2022-2030.

The global cancer biomarker market has been segmented based on cancer type, technology, application, and regions. The breast cancer segment led the market in 2021.

North America region emerged as the largest market for cancer biomarkers.

The market's growth will be influenced by increasing incidences of cancer.

Technical issues in sample collection could hamper the market growth.

The rising demand for personalized medicines will provide huge opportunities to the market.

Key players are Abbott Laboratories, Bristol-Myers Squibb Company, Merck KGaA, Bio-Rad Laboratories, PerkinElmer, F.Hoffmann-La Roche Ltd., Qiagen N.V., Exact Sciences Corporation, Thermo Fisher Scientific, and Siemens AG.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Cancer Type
          4.3.2. Market Attractiveness Analysis By Technology
          4.3.3. Market Attractiveness Analysis By Application
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing incidences of cancer
    5.3. Restraints
          5.3.1. Technical issues in sample collection
    5.4. Opportunities
          5.4.1. Rising demand for personalized medicines
    5.5. Challenges
          5.5.1. Lack of reimbursement policies

6. Global Cancer Biomarkers Market Analysis and Forecast, By Cancer Type
    6.1. Segment Overview
    6.2. Breast
    6.3. Lung
    6.4. Leukemia
    6.5. Colorectal
    6.6. Melanoma
    6.7. Others

7. Global Cancer Biomarkers Market Analysis and Forecast, By Technology
    7.1. Segment Overview
    7.2. Cytogenetics Based Tests
    7.3. Imaging Technologies
    7.4. Omics Technologies
    7.5. Immunoassays

8. Global Cancer Biomarkers Market Analysis and Forecast, By Application
    8.1. Segment Overview
    8.2. Drug Discovery and Development
    8.3. Diagnostics
    8.4. Risk Assessment
    8.5. Prognostics
    8.6. Others

9. Global Cancer Biomarkers Market Analysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Cancer Biomarkers Market-Competitive Landscape
    10.1. Overview
          10.1.1. Market Share of Key Players in the Cancer Biomarkers Market
          10.1.2. Global Company Market Share
          10.1.3. North America Company Market Share
          10.1.4. Europe Company Market Share
          10.1.5. APAC Company Market Share
    10.2. Competitive Situations and Trends
          10.2.1. Cancer Launches and Developments
          10.2.2. Partnerships, Collaborations, and Agreements
          10.2.3. Mergers & Acquisitions
          10.2.4. Expansions

11. Company Profiles
    11.1. Abbott Laboratories
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Component Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. Bristol-Myers Squibb Company
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Component Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. Merck KGaA
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Component Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Bio-Rad Laboratories
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Component Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. PerkinElmer
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Component Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. F.Hoffmann-La Roche Ltd.
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Component Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. Qiagen N.V.
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Component Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. Exact Sciences Corporation
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Component Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. Thermo Fisher Scientific
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Component Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis
    11.10. Siemens AG
          11.10.1. Business Overview
          11.10.2. Company Snapshot
          11.10.3. Company Market Share Analysis
          11.10.4. Company Component Portfolio
          11.10.5. Recent Developments
          11.10.6. SWOT Analysis
 

List of Table

1. Global Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

2. Global Breast Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

3. Global Lung Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

4. Global Leukemia Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

5. Global Colorectal Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

6. Global Melanoma Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

7. Global Others Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

8. Global Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

9. Global Cytogenetics Based Tests Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

10. Global Imaging Technologies Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

11. Global Omics Technologies Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

12. Global Immunoassays Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

13. Global Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

14. Global Drug Discovery and Development Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

15. Global Diagnostics Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

16. Global Risk Assessment Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

17. Global Prognostics Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion)

18. Global Others Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

19. Global Cancer Biomarkers Market, By Region, 2019-2030 (USD Billion) 

20. North America Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

21. North America Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

22. North America Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

23. U.S. Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

24. U.S. Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

25. U.S. Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

26. Canada Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

27. Canada Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

28. Canada Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

29. Mexico Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

30. Mexico Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

31. Mexico Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

32. Europe Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

33. Europe Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

34. Europe Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

35. Germany Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

36. Germany Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

37. Germany Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

38. France Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

39. France Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

40. France Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

41. U.K. Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

42. U.K. Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

43. U.K. Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

44. Italy Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

45. Italy Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

46. Italy Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

47. Spain Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

48. Spain Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

49. Spain Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

50. Asia Pacific Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

51. Asia Pacific Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

52. Asia Pacific Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

53. Japan Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

54. Japan Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

55. Japan Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

56. China Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

57. China Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

58. China Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

59. India Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

60. India Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

61. India Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

62. South America Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

63. South America Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

64. South America Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

65. Brazil Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

66. Brazil Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

67. Brazil Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

68. Middle East and Africa Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

69. Middle East and Africa Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

70. Middle East and Africa Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

71. UAE Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

72. UAE Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

73. UAE Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

74. South Africa Cancer Biomarkers Market, By Cancer Type, 2019-2030 (USD Billion) 

75. South Africa Cancer Biomarkers Market, By Technology, 2019-2030 (USD Billion) 

76. South Africa Cancer Biomarkers Market, By Application, 2019-2030 (USD Billion) 

List of Figures 

1. Global Cancer Biomarkers Market Segmentation

2. Cancer Biomarkers Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Cancer Biomarkers Market Attractiveness Analysis By Cancer Type

9. Global Cancer Biomarkers Market Attractiveness Analysis By Technology

10. Global Cancer Biomarkers Market Attractiveness Analysis By Application

11. Global Cancer Biomarkers Market Attractiveness Analysis By Region

12. Global Cancer Biomarkers Market: Dynamics

13. Global Cancer Biomarkers Market Share by Cancer Type (2022 & 2030)

14. Global Cancer Biomarkers Market Share by Technology (2022 & 2030)

15. Global Cancer Biomarkers Market Share by Application (2022 & 2030)

16. Global Cancer Biomarkers Market Share by Regions (2022 & 2030)

17. Global Cancer Biomarkers Market Share by Company (2021)

This study forecasts revenue at global, regional, and country levels from 2022 to 2030. The Brainy Insights has segmented the global cancer biomarkers market based on the below-mentioned segments:

Global Cancer Biomarkers Market by Cancer Type:

  • Breast
  • Lung
  • Leukemia
  • Colorectal
  • Melanoma
  • Others

Global Cancer Biomarkers Market by Technology:

  • Cytogenetics Based Tests
  • Imaging Technologies
  • Omics Technologies
  • Immunoassays

Global Cancer Biomarkers Market by Application:

  • Drug Discovery and Development
  • Diagnostics
  • Risk Assessment
  • Prognostics
  • Others

Global Cancer Biomarkers Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date